{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T03:26:28Z","timestamp":1794281188897,"version":"4.9.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T00:00:00Z","timestamp":1762473600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100009857","name":"Regeneron Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100009857","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aaojournal.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Ophthalmology"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1016\/j.ophtha.2025.10.028","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T03:54:24Z","timestamp":1762833264000},"page":"577-588","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":24,"title":["Intravitreal Aflibercept 8 mg for Diabetic Macular Edema"],"prefix":"10.1016","volume":"133","author":[{"given":"Diana V.","family":"Do","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Wykoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sobha","family":"Sivaprasad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-5766","authenticated-orcid":false,"given":"David M.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9219-1614","authenticated-orcid":false,"given":"David S.","family":"Boyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0287-3801","authenticated-orcid":false,"given":"Taiji","family":"Sakamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Win","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sunir","family":"Joshi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2631-7754","authenticated-orcid":false,"given":"Hani","family":"Salehi-Had","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8260-3566","authenticated-orcid":false,"given":"Andr\u00e1s","family":"Seres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alyson J.","family":"Berliner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7870-0478","authenticated-orcid":false,"given":"Sergio","family":"Leal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karen W.","family":"Chu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly","family":"Reed","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yenchieh","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-8051-4201","authenticated-orcid":false,"given":"Rafia","family":"Bhore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhanying","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ursula","family":"Schmidt-Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Schmelter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9035-7895","authenticated-orcid":false,"given":"Andrea","family":"Schulze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0673-012X","authenticated-orcid":false,"given":"Zoran","family":"Hasanbasic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Morgan-Warren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2829-3602","authenticated-orcid":false,"given":"Boaz","family":"Hirshberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George D.","family":"Yancopoulos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ophtha.2025.10.028_bib1","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2017.01.003","article-title":"Gene therapy for diabetic retinopathy: are we ready to make the leap from bench to bedside?","volume":"173","author":"Wang","year":"2017","journal-title":"Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.ophtha.2025.10.028_bib2","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/S2213-8587(16)30052-3","article-title":"Diabetic macular oedema","volume":"5","author":"Tan","year":"2017","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"4","key":"10.1016\/j.ophtha.2025.10.028_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1159\/000458539","article-title":"Guidelines for the management of diabetic macular edema by the European Society of Retina Specialists (EURETINA)","volume":"237","author":"Schmidt-Erfurth","year":"2017","journal-title":"Ophthalmologica"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.028_bib4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1016\/j.ophtha.2019.09.025","article-title":"Diabetic retinopathy Preferred Practice Pattern\u00ae","volume":"127","author":"Flaxel","year":"2020","journal-title":"Ophthalmology"},{"issue":"33","key":"10.1016\/j.ophtha.2025.10.028_bib5","doi-asserted-by":"crossref","first-page":"23463","DOI":"10.1074\/jbc.274.33.23463","article-title":"Vascular endothelial growth factor induces rapid phosphorylation of tight junction proteins occludin and zonula occluden 1. A potential mechanism for vascular permeability in diabetic retinopathy and tumors","volume":"274","author":"Antonetti","year":"1999","journal-title":"J Biol Chem"},{"issue":"4","key":"10.1016\/j.ophtha.2025.10.028_bib6","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1016\/j.ophtha.2011.12.039","article-title":"Ranibizumab for diabetic macular edema: results from 2 phase III randomized trials: RISE and RIDE","volume":"119","author":"Nguyen","year":"2012","journal-title":"Ophthalmology"},{"issue":"11","key":"10.1016\/j.ophtha.2025.10.028_bib7","doi-asserted-by":"crossref","first-page":"2247","DOI":"10.1016\/j.ophtha.2014.05.006","article-title":"Intravitreal aflibercept for diabetic macular edema","volume":"121","author":"Korobelnik","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.028_bib8","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.diabres.2018.02.023","article-title":"IDF diabetes atlas: global estimates of diabetes prevalence for 2017 and projections for 2045","volume":"138","author":"Cho","year":"2018","journal-title":"Diabetes Res Clin Pract"},{"issue":"3","key":"10.1016\/j.ophtha.2025.10.028_bib9","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1016\/j.ophtha.2019.10.019","article-title":"Treatment patterns for diabetic macular edema: an Intelligent Research in Sight (IRIS\u00ae) registry analysis","volume":"127","author":"Cantrell","year":"2020","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ophtha.2025.10.028_bib10","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.oret.2018.06.004","article-title":"Real-world outcomes of anti-vascular endothelial growth factor therapy in diabetic macular edema in the United States","volume":"2","author":"Ciulla","year":"2018","journal-title":"Ophthalmol Retina"},{"issue":"6","key":"10.1016\/j.ophtha.2025.10.028_bib11","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.survophthal.2016.03.010","article-title":"Vascular endothelial growth factor and diabetic macular edema","volume":"61","author":"Lally","year":"2016","journal-title":"Surv Ophthalmol"},{"issue":"12","key":"10.1016\/j.ophtha.2025.10.028_bib12","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.1007\/s12325-022-02326-8","article-title":"Outcomes of over 40,000 eyes treated for diabetic macula edema in routine clinical practice: a systematic review and meta-analysis","volume":"39","author":"Mehta","year":"2022","journal-title":"Adv Ther"},{"issue":"2","key":"10.1016\/j.ophtha.2025.10.028_bib13","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1136\/bjophthalmol-2020-315933","article-title":"Visual acuity outcomes and anti-VEGF therapy intensity in diabetic macular oedema: a real-world analysis of 28 658 patient eyes","volume":"105","author":"Ciulla","year":"2021","journal-title":"Br J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.028_bib14","first-page":"311","article-title":"Patient experience survey of anti-vascular endothelial growth factor treatment for neovascular age-related macular degeneration and diabetic macular edema","volume":"67","author":"Holekamp","year":"2024","journal-title":"Ophthalmic Res"},{"key":"10.1016\/j.ophtha.2025.10.028_bib15","series-title":"Do we need more VEGF blockade? The rationale for a clinical trial testing high-dose aflibercept","author":"Brown","year":"2020"},{"issue":"4","key":"10.1016\/j.ophtha.2025.10.028_bib16","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1097\/IAE.0000000000002566","article-title":"Pharmacokinetic study of intravitreal aflibercept in humans with neovascular age-related macular degeneration","volume":"40","author":"Do","year":"2020","journal-title":"Retina"},{"issue":"8","key":"10.1016\/j.ophtha.2025.10.028_bib17","doi-asserted-by":"crossref","first-page":"1658","DOI":"10.1016\/j.ophtha.2012.02.010","article-title":"One-year outcomes of the da Vinci Study of VEGF Trap-Eye in eyes with diabetic macular edema","volume":"119","author":"Do","year":"2012","journal-title":"Ophthalmology"},{"issue":"6","key":"10.1016\/j.ophtha.2025.10.028_bib18","doi-asserted-by":"crossref","first-page":"1098","DOI":"10.1016\/j.ophtha.2011.03.020","article-title":"The 1-year results of CLEAR-IT 2, a phase 2 study of vascular endothelial growth factor trap-eye dosed as-needed after 12-week fixed dosing","volume":"118","author":"Heier","year":"2011","journal-title":"Ophthalmology"},{"issue":"5","key":"10.1016\/j.ophtha.2025.10.028_bib19","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1016\/j.ophtha.2012.10.014","article-title":"Twelve-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"120","author":"Busbee","year":"2013","journal-title":"Ophthalmology"},{"issue":"12","key":"10.1016\/j.ophtha.2025.10.028_bib20","doi-asserted-by":"crossref","first-page":"1538","DOI":"10.1038\/eye.2015.142","article-title":"Month-6 primary outcomes of the READ-3 study (Ranibizumab for Edema of the mAcula in Diabetes-Protocol 3 with high dose)","volume":"29","author":"Do","year":"2015","journal-title":"Eye (Lond)"},{"issue":"11","key":"10.1016\/j.ophtha.2025.10.028_bib21","doi-asserted-by":"crossref","first-page":"2181","DOI":"10.1016\/j.ophtha.2014.05.009","article-title":"Twenty-four-month efficacy and safety of 0.5 mg or 2.0 mg ranibizumab in patients with subfoveal neovascular age-related macular degeneration","volume":"121","author":"Ho","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.028_bib22","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ajo.2022.01.004","article-title":"KESTREL and KITE: 52-week results from two phase III pivotal trials of brolucizumab for diabetic macular edema","volume":"238","author":"Brown","year":"2022","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.028_bib23","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1016\/j.ophtha.2019.04.017","article-title":"HAWK and HARRIER: phase 3, multicenter, randomized, double-masked trials of brolucizumab for neovascular age-related macular degeneration","volume":"127","author":"Dugel","year":"2020","journal-title":"Ophthalmology"},{"issue":"10","key":"10.1016\/j.ophtha.2025.10.028_bib24","doi-asserted-by":"crossref","first-page":"2044","DOI":"10.1016\/j.ophtha.2015.06.017","article-title":"Intravitreal aflibercept for diabetic macular edema: 100-week results from the VISTA and VIVID studies","volume":"122","author":"Brown","year":"2015","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.028_bib25","series-title":"Eylea [package insert]","author":"Regeneron Pharmaceuticals Inc","year":"2023"},{"key":"10.1016\/j.ophtha.2025.10.028_bib26","series-title":"Eylea [summary of product characteristics]","year":"2023"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.028_bib27","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.oret.2018.08.002","article-title":"A multinational comparison of anti-vascular endothelial growth factor use: the United States, the United Kingdom, and Asia-Pacific","volume":"3","author":"Parikh","year":"2019","journal-title":"Ophthalmol Retina"},{"issue":"11","key":"10.1016\/j.ophtha.2025.10.028_bib28","doi-asserted-by":"crossref","first-page":"3489","DOI":"10.1007\/s00417-022-05703-9","article-title":"Intravitreal aflibercept for diabetic macular edema in real-world clinical practice in Japan: 24-month outcomes","volume":"260","author":"Sugimoto","year":"2022","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"key":"10.1016\/j.ophtha.2025.10.028_bib29","series-title":"Eylea [product information]","year":"2015"},{"issue":"9","key":"10.1016\/j.ophtha.2025.10.028_bib30","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1001\/jamaophthalmol.2023.2421","article-title":"Effect of high-dose intravitreal aflibercept, 8 mg, in patients with neovascular age-related macular degeneration: the phase 2 CANDELA randomized clinical trial","volume":"141","author":"Wykoff","year":"2023","journal-title":"JAMA Ophthalmol"},{"issue":"10432","key":"10.1016\/j.ophtha.2025.10.028_bib31","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1016\/S0140-6736(23)02577-1","article-title":"Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2\/3 trial","volume":"403","author":"Brown","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ophtha.2025.10.028_bib32","series-title":"Eylea HD [summary of product characteristics]","year":"2024"},{"key":"10.1016\/j.ophtha.2025.10.028_bib33","series-title":"Eylea HD [summary of product characteristics]","year":"2024"},{"key":"10.1016\/j.ophtha.2025.10.028_bib34","series-title":"Eylea HD [package insert]","year":"2023"},{"key":"10.1016\/j.ophtha.2025.10.028_bib35","series-title":"Vabysmo [package insert]","year":"2024"},{"issue":"6","key":"10.1016\/j.ophtha.2025.10.028_bib36","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/j.ophtha.2023.12.026","article-title":"Faricimab treat-and-extend for diabetic macular edema: two-year results from the randomized phase 3 YOSEMITE and RHINE trials","volume":"131","author":"Wong","year":"2024","journal-title":"Ophthalmology"},{"key":"10.1016\/j.ophtha.2025.10.028_bib37","series-title":"Beovu [package insert]","year":"2023"},{"key":"10.1016\/j.ophtha.2025.10.028_bib38","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.ajo.2023.07.012","article-title":"KESTREL and KITE phase 3 studies: 100-week results with brolucizumab in patients with diabetic macular edema","volume":"260","author":"Wykoff","year":"2023","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"10.1016\/j.ophtha.2025.10.028_bib39","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s40123-019-00224-x","article-title":"Clinical outcomes of a treat and extend regimen with intravitreal aflibercept injections in patients with diabetic macular edema: experience in clinical practice","volume":"9","author":"Curry","year":"2020","journal-title":"Ophthalmol Ther"},{"key":"10.1016\/j.ophtha.2025.10.028_bib40","series-title":"Aflibercept 8 mg in DME: key results from the PHOTON extension study","author":"Do","year":"2024"}],"container-title":["Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025007079?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0161642025007079?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T01:11:56Z","timestamp":1792804316000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0161642025007079"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":40,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["S0161642025007079"],"URL":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.10.028","relation":{},"ISSN":["0161-6420"],"issn-type":[{"value":"0161-6420","type":"print"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Intravitreal Aflibercept 8 mg for Diabetic Macular Edema","name":"articletitle","label":"Article Title"},{"value":"Ophthalmology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ophtha.2025.10.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 by the American Academy of Ophthalmology.","name":"copyright","label":"Copyright"}]}}